These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3315585)

  • 21. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Jackson D
    Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of reperfusion on electrocardiographic and enzymatic infarct size: results of a randomized multicenter study of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction.
    Hackworthy RA; Sorensen SG; Fitzpatrick PG; Barry WH; Menlove RL; Rothbard RL; Anderson JL
    Am Heart J; 1988 Oct; 116(4):903-14. PubMed ID: 3051985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
    Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
    Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW
    Ann Intern Med; 1986 Mar; 104(3):304-10. PubMed ID: 3511819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic assessment of patency and reocclusion: preliminary results of the Dutch APSAC Reocclusion Multicenter Study (ARMS).
    Visser RF
    Clin Cardiol; 1990 Mar; Suppl 5():V45-7; discussion V67-72. PubMed ID: 2182241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
    J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A european multicenter and randomized study of APSAC versus streptokinase in myocardial infarction].
    Charbonnier B; Cribier A; Monassier JP; Favier JP; Materne P; Brochier ML; Letac B; Hanssen M; Sacrez A; Kulbertus H
    Arch Mal Coeur Vaiss; 1989 Sep; 82(9):1565-71. PubMed ID: 2510677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Rothbard RL
    Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
    Monk JP; Heel RC
    Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.
    Hellstern P; Doenecke P; Köhler M; Schwerdt H; Ozbek C; Miyashita C; Bette L; Wenzel E
    Drugs; 1987; 33 Suppl 3():183-5. PubMed ID: 3315589
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 39. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
    Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ
    Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
    Bassand JP; Bernard Y; Lusson JR; Machecourt J; Cassagnes J; Borel E
    Clin Cardiol; 1990 Mar; Suppl 5():V39-44; discussion V67-72. PubMed ID: 2182240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.